Roivant Sciences

Yahoo Finance • 10 days ago

This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.

Quick Read The State Street SPDR S&P Biotech ETF (XBI) has gained 58% over the past year and trades at $128, with potential for nearly 50 points of upside to reach its 2021 all-time high of $175. Top holdings include Moderna (2.25%), Roiv... Full story

Yahoo Finance • 11 days ago

Immunovant falls on late-stage trial setback for TED therapy

[Stethoscope with the word Thyroid Disorders.] Fauzi Muda/iStock via Getty Images Immunovant (IMVT [https://seekingalpha.com/symbol/IMVT]) shares lost ~10% in the premarket on Thursday after the company, a subsidiary of Roivant Sciences (... Full story

Yahoo Finance • 11 days ago

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, high... Full story

Yahoo Finance • 11 days ago

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, high... Full story

Yahoo Finance • 16 days ago

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in dermatomyositis Brepocitinib 30 mg was superior to placebo on th... Full story

Yahoo Finance • 19 days ago

Bernstein Initiates Coverage of Roivant Sciences Ltd. (ROIV) with an Outperform Rating

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the 12 Best UK Stocks to Buy According to Hedge Funds. On March 19, 2026, Bernstein initiated coverage of Roivant Sciences Ltd. (NASDAQ:ROIV) with an Outperform rating and a $35 price target,... Full story

Yahoo Finance • 29 days ago

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

On February 17, 2026, Logos Global Management LP disclosed in a Securities and Exchange Commission filing that it bought 1,100,000 shares of Immunovant(NASDAQ:IMVT), an estimated $24.53 million trade based on quarterly average pricing. Lo... Full story

Yahoo Finance • last month

Moderna gains as Arbutus/ Genevant settlement removes major financial risk

[Massachusetts Based Biotech Company Moderna Receives FDA Approval To Continue Coronavirus Vaccine Trials] Maddie Meyer/Getty Images News Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) shares continued to rise in the premarket on W... Full story

Yahoo Finance • last month

Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang

March 4 (Reuters) - Moderna shares rose 10% in premarket trading on Wednesday after the company settled a long-running legal battle over the ‌technology that made its COVID-19 vaccine possible, removing an overhang and ‌allowing it to focu... Full story

Yahoo Finance • last month

Stocks to Watch Wednesday: CrowdStrike, Gitlab, Moderna, Strategy

↘️ GitLab (GLTB): The software-development tools company said it expects slower annual sales growth, stoking concerns around the threat artificial intelligence poses for the sector. Shares fell 9% in premarket trading. Continue Reading... Full story

Yahoo Finance • last month

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Arbutus Biopharma Corporation Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal If the $1.3 billion payment is realized, this se... Full story

Yahoo Finance • last month

Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

Roivant Sciences Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal If the $1.3 billion payment is realized, this settlement will... Full story

Yahoo Finance • last month

FDA Grants Priority Review For Priovant's Brepocitinib For Dermatomyositis

(RTTNews) - Priovant Therapeutics, a subsidiary of Roivant Sciences Ltd. (ROIV), on Tuesday said the U.S. Food and Drug Administration has accepted its new drug application for brepocitinib and granted it priority review for the treatment... Full story

Yahoo Finance • 2 months ago

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position

On February 17, 2026, Perceptive Advisors reported a buy of Celcuity(NASDAQ:CELC), adding 203,881 shares in the fourth quarter, with an estimated transaction value of $16.76 million based on quarterly average pricing. What happened Accor... Full story

Yahoo Finance • 2 months ago

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction

On February 17, 2026, Perceptive Advisors disclosed a buy of 978,662 shares of Apogee Therapeutics(NASDAQ:APGE), with an estimated transaction value of $61.64 million based on quarterly average pricing. What happened According to a Febru... Full story

Yahoo Finance • 2 months ago

Dolby Stock Down 18%, Yet This $8 Million Bet Signals Turnaround Potential

Key Points Neo Ivy Capital Management acquired 117,964 shares of DLB in the fourth quarter. The quarter-end stake value increased by $7.58 million due to the new shares acquired. DLB position accounts for 1.2% of fund AUM, placing it ins... Full story

Yahoo Finance • 2 months ago

Stocks Rebound on Positive Tech Earnings

The S&P 500 Index ($SPX) (SPY) today is up +1.20%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +1.48%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.26%.  March E-mini S&P futures (ESH26) are up +1.21%, and March E-mini Nasdaq fu... Full story

Yahoo Finance • 2 months ago

Wall Street Set to Open Modestly Higher Friday as Tech Stocks Stabilize Following Week-Long Rout

US equities look set to open slightly higher in Friday's trading session with tech stocks rebounding PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

PHocus enrollment completed in under 12 months from first patient dosed, representing a rapid enrollment pace in pulmonary hypertension associated with interstitial lung diseaseTopline results on track for second half of calendar year 2026... Full story

Yahoo Finance • 2 months ago

Stocks Settle Lower as Tech and Crypto are Routed

The S&P 500 Index ($SPX) (SPY) on Thursday closed down -1.23%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -1.20%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -1.38%.  March E-mini S&P futures (ESH26) fell -1.23%, and... Full story